RankingsPricing
  1. US-listed companies
  2. Kiniksa Pharmaceuticals International, plc
  3. Raw

Kiniksa Pharmaceuticals International, plcKNSA

Market cap
$6.1B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Cash and cash equivalents7247114122123108184
Short-term investments23518620960689860
Accounts receivable, net---4132142
Contract asset----8--
Inventory---4223126
Prepaid expenses and other current assets68107111820
Total current assets314242333196243276332
Property and equipment, net6643211
Operating lease right-of-use assets-27651210
Other long-term assets--696110
Intangible asset, net---19181716
Deferred tax assets-40-185219211
Total assets322255349233460526581
Accounts payable11612882
Accrued collaboration expenses------48
Accrued expenses16202938304532
Deferred revenue-----0-
Operating lease liabilities-223322
Other current liabilities00026816
Total current liabilities432832454764101
Non-current deferred revenue----121232
Operating Lease, Liability, Noncurrent-1533108
Other long-term liabilities-010222
Total liabilities432938486487142
Class A ordinary shares0000000
Class B ordinary shares0000000
Class A1 ordinary shares-000000
Class B1 ordinary shares-000000
Additional paid-in capital473581829860888917960
Accumulated other comprehensive income (loss)-00-0-000-0
Accumulated deficit-194-356-517-675-492-478-521
Total shareholders' equity279225312185396439438
Total liabilities and shareholders' equity322255349233460526581